Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 14/20 | 0.40 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.34 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314527 | 0.92 | ITGB3 (0.41) | SUCNR1OXGR1HDAC3HDAC1HDAC2 | |
| SCHEMBL20157747 | 0.89 | DRD2 (0.43) | SUCNR1OXGR1HDAC3HDAC1HDAC2 | |
| SCHEMBL21314447 | 0.85 | WDR5 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21314446 | 0.85 | WDR5 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21317534 | 0.82 | ITGAV (0.55) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL30487506 | 0.82 | ITGAV (0.55) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL30487482 | 0.82 | HDAC1 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30487541 | 0.78 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL28744044 | 0.78 | ITGB3 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL20142411 | 0.77 | SUCNR1 (0.34) | SUCNR1OXGR1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | SUCNR1 2279/4885OXGR1 697/4885HDAC3 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.